알티뮨(ALT)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.25 (+0.31%), 시가총액 $554.25M, 52주 범위 $2.60 ~ $7.71.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
알티뮨의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
알티뮨의 현재 주가는 $3.25 (+0.31%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
알티뮨의 시가총액은 약 $554.25M입니다.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.